1.
Evens R,
Kaitin K. “The Evolution of Biotechnology and Its Impact on Health Care.”
Health Affairs. 2015;34(2):210–219.
2.
Jinek M,
Chylinski K,
Fonfara I,
Hauer M,
Doudna JA,
Charpentier E. “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity.”
Science. 2012;337(6096):816–821. See also
Platt RJ,
Chen S,
Zhou Y, et al. “CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling.”
Cell. 2014;159(2):440–455. See also Ruby T, Singh N. “Realizing the Potential of CRISPR: Three Healthcare Executives Share Industry Perspectives on the Future of Genome Editing.” McKinsey, January 2017.
3.
Paine J,
Shipton CA,
Chaggar S, et al. “Improving the Nutritional Value of Golden Rice through Increased Pro-vitamin A Content.”
Nature Biotechnology. 2005;23(4):482–487. See also
Simon F,
Kotler P. Building Global Biobrands: Taking Biotechnology to Market.
New York:
Free Press; 2003; p. 4.
4.
Greenwood J. “Unleashing the Promise of Biotechnology to Help Heal, Fuel and Feed the World.” In: Shimasaki C, ed. Biotechnology Entrepreneurship: Starting, Managing and Leading Biotech Companies.
Waltham, MA:
Elsevier; 2004: 3–13. See also
Friedman Y. Building Biotechnology.
Washington, DC:
Logos Press; 2014.
5.
Clark D,
Strumpf D. “Tech Stalwarts Soar to New Highs.”
Wall Street Journal. October 24, 2015; Eisen B, Dieterich C, “Apple Market Cap Tops $800 Billion”. Wall Street Journal. May 10, 2017; market cap for Johnson & Johnson, Capital IQ, May 2017.
6. World Health Organization. MHealth: New Horizons for Health through Mobile Technologies. Global Observatory for eHealth Series, volume 3, 2011; cited in IMS Health Research Institute, Patient Adoption of mHealth, September 2015.
7. PWC Health Research Institute. Health Wearables: The Early Days. 2014.
8.
Dormehl L. “Why the Anthem Security Breach Was Such a Wake-Up Call for the Health Industry.”
Fast Company. February 6, 2015.
9.
Steinberg D,
Horwitz G,
Zohar D. “Building a Business Model in Digital Medicine.”
Nature Biotechnology. 2015;33(9):910–920.
10. Forrester Research. The State of Consumers and Technology: Benchmark 2015, US.
11. IMS Institute for Healthcare Informatics. Patient Adoption of mHealth, September 2015.
12. Steinberg D, Horwitz G, Zohar D. “Building a Business Model in Digital Medicine.” Nature Biotechnology. 2015;33(9):910–920.
13.
Miller R. “Proteus Seeks Pharma Partnerships for Ingestible Sensors.”
The Gray Sheet. July 15, 2015.
14.
Neil R. “The Digital Healthcare Revolution Picks Up Speed.”
MedTech Insight. July 14, 2015.
18.
Jack Young, former leader of dRx Capital at Qualcomm, interview by Françoise Simon, September 16, 2015. Don Jones, Chief Digital Officer, Scripps Translational Research Institute, interview by Françoise Simon, October 2, 2015; see also dRX Capital website, http://www.dRxcapital.com.
19. Simon F, Kotler P. Building Global Biobrands: Taking Biotechnology to Market, Free Press, New York, 2003; p. 35.
20.
Paul Grundy, IBM Global Director of Healthcare Transformation, interview by Françoise Simon, October 22, 2015.
21. IBM Annual Report/SEC Form 10 K, February 24, 2015; see also IBM Annual Report 2016.
32. Calico. “AbbVie and Calico Announce a Novel Collaboration to Accelerate the Discovery, Development and Commercialization of New Therapies.” http://www.calicolabs.com/news/2014/09/03/. Published September 3, 2014. Accessed April 18, 2017.
38.
Friend S. “App-Enabled Trial Participation: Tectonic Shift or Tepid Rumble?”
Science Translational Medicine. 2015;7(297):297ed10.
Chapter 2
1.
Hay M,
Thomas D,
Craighead J,
Economides C,
Rosenthal J. “Clinical Development Success Rates for Investigational Drugs.”
Nature Biotechnology. 2014;32(1):40–51.
4. Tufts Center for the Study of Drug Development. How the Tufts Center for the Study of Drug Development Pegged the Cost of a New Drug at $2.6 Billion.
Boston:
Tufts University; 2014. Available at http://csdd.tufts.edu/files/uploads/cost_study_backgrounder.pdf. Accessed April 19, 2017.
5. Data derived from the respective companies' financial statements, available at US Securities and Exchange Commission Website, EDGAR Company Search. http://www.sec.gov/edgar/searchedgar/companysearch.html. Accessed April 19, 2017.
13. EY analysis based on various primary data sources, including review of the financial statements included in the relevant IPO documents and Capital IQ and VentureSource databases.
4.
Lo A,
Pisano G. “Lessons from Hollywood: A New Approach to Funding R&D.”
MIT Sloan Management Review. 2015;57 (2).
Bernal L. “Why Pharma Must Go Hollywood.”
The Scientist. 2017;21 (2):42–45.
5. Morgan Stanley Research. “Pharmaceuticals: Exit Research and Create Value.” January 20, 2010.
6.
Bluestein A. “Will Johnson & Johnson's New Innovation Centers Point the Way Toward Its Future?”
Fast Company. http://www.fastcompany.com/3025556/keeping-up-with-the-johnsons. Published January 20, 2010. Accessed April 20, 2017.
Senior M. “J&J Courts Biotech in Clusters.”
Nature Biotechnology. 2013;31; 769–770.
20.
Menzel G,
Xanthopoulos K. “Securing a Partner Is Only the Beginning—You then Have to Put Substantial Effort and Resources into Keeping the Collaboration Functioning and Productive.” Bioentrepreneur (Nature Biotechnology) Website. http://www.nature.com/bioent/2012/120201/full/bioe.2012.2.html. Published February 23, 2012. Accessed April 20, 2017.
5. Mara Aspinall, Executive Chairman of GenePeeks and CA Therapeutics and cofounder of the School of Biomedical Diagnostics, personal correspondence, February 2016.
11. Lincoln Nadauld, Director, Cancer Genomics at InterMountain Healthcare, personal correspondence, February 2016.
12.
Nadauld L,
Van Norman SB,
Fulde G, et al. “Precision Medicine to Improve Survival Without Increasing Costs in Advanced Cancer Patients.”
Journal of Clinical Oncology. 2015; 33. (suppl; abstr e17641). Available at http://meetinglibrary.asco.org/content/152750-156. Accessed April 21, 2017.
19. US Food and Drug Administration. “FDA Approves First Companion Diagnostic to Detect Gene Mutation Associated with a Type of Lung Cancer.” May 13, 2014.
23.
Armour A,
Watkins C. “The Challenge of Targeting EGFR: Experience with Gefitinib in Non-Small Cell Lung Cancer.”
European Respiratory Review. 2010;19: 186–196. Available at http://err.ersjournals.com/content/19/117/186. Accessed April 21, 2017.
28.
Getz K,
Stergiopoulos,
Kim JY. “The Adoption and Impact of Adaptive Trial Designs.”
R&D Senior Leadership Brief.
Boston, MA: Tufts Center for the Study of Drug Development, February 13, 2013. Available at https://www.iconplc.com/icon-files/docs/thought-leadership/premium/TuftsCSDD_Adaptive-Design-Trials-Sr-Mgmt-Brief_May2013.pdf. Accessed April 21, 2017. See also Woodcock J, Lavange L. “Master Protocols To Study Multiple Therapies, Multiple Diseases, Or Both.” New England Journal Of Medicine 2017; 377:62-70. Accessed July 17, 2017.
29.
Schork N. “Personalized Medicine: Time for One-Person Trials.”
Nature. 2015;520: 609–611. Available at http://www.nature.com/news/personalized-medicine-time-for-one-person-trials-1.17411. Accessed April 21, 2017. See also Demeyin W, Frost J, Ukoumunne O, Briscoe S, Britten N. “N of 1 Trials and the Optimal Individualisation of Drug Treatments: A Systematic Review.” Systematic Reviews 2017 6:90. Accessed July 17, 2017.
30.
Hayes D, et al. “Breaking a Vicious Cycle.”
Science Translational Medicine. 2013;5, 196cm6.
33.
Pothier K,
Gustavsen G. “Combating Complexity: Partnerships in Personalized Medicine.”
Personalized Medicine. 2013;10(4):387–396.
34.
Hayes D, et al. “Breaking a Vicious Cycle.” Science Translational Medicine. 2013;5, 196cm6.
35. National Institute of Health and Care Excellence. “EGFR-TK Mutation Testing in Adults with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer.” NICE Diagnostics Guidance. https://www.nice.org.uk/guidance/dg9/chapter/3-Clinical-need-and-practice. Published August 2013. Accessed April 21, 2017.
36.
Domchek SM,
Bradbury A,
Garber JE,
Offit K,
Robson ME. “Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?”
Journal of Clinical Oncology. 2013;31(10):1267–1270.
54.
Tom Miller, cofounder and managing partner, GreyBird Ventures, personal correspondence, February 8, 2016.
55.
Mara Aspinall, executive chairman of GenePeeks and CA Therapeutics and cofounder of the School of Biomedical Diagnostics, personal correspondence, February 2016.
1.
Loftus P. “US Drug Spending Climbs.”
Wall Street Journal. April 14, 2016; B3; see also Aitken M, “Medicines Use and Spending in the US,” Quintiles IMS Institute, May 2017.
2. Aitken M, Outlook for Global Medicines Through 2021, Quintiles IMS Institute, December 2016.
3.
Birth A.“Whether Prescribed or Over-The-Counter, Americans Prefer Generics.” Harris Poll. December 2, 2015.
5. Experts in Chronic Myeloid Leukemia,
Abboud C,
Berman E, et al. “The Price of Drugs for Chronic Myeloid Leukemia (CML) Is a Reflection of the Unsustainable Prices of Cancer Drugs: From the Perspective of a Large Group of CML Experts.”
Blood. 2013;121(22):4439–4442.
6.
Bennette C,
Richards C,
Sullivan S, et al. “Steady Increases in Prices for Oral Anticancer Drugs after Market Launch Suggest a Lack of Competitive Pressures.”
Health Affairs. 2016;35 (5):805–812.
8.
Kaplan H.“Preparing for the Zero Moment of Truth: Managing Early Awareness in Rare Disease Drug Commercialization.” In Vivo. April 13, 2016.
9. “Patient Engagement and Patient Use of Evidence.”
Health Affairs. 2016; 35(4):744.
10.
Wenzel M,
Hall C.“Opposites Attract: Pairing R&D and Commercial Teams.” Pharmaceutical Executive. May 5, 2015. Available at http://www.pharmexec.com/opposites-attract-pairing-rd-and-commercial-teams. Accessed April 26, 2017. See also
Bailey CJ. “Why Is Exubera Being Withdrawn?”
British Medical Journal. 2007; 335(7630):1156.
18.
Simon F,
Kotler P, op. cit, 142–143. See also
Merrill J.“Among New Drug Launches, Oncology Scores Big While CV Lags.” Pink Sheet. March 28, 2016.
Sutter S.“Pitting Crestor Against Lipitor Misses the Mark.” Pink Sheet. September 5, 2011. For Crestor sales, see Pharmacompass, “Top Drugs by Sales Revenue in 2015, Who Sold the Biggest Blockbuster Drugs,” March 10, 2016. Available at https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-revenue-in-2015-who-sold-the-biggest-blockbuster-drugs. Accessed April 26, 2017.
19. The Top 15 Best-Selling Drugs of 2016, op. cit.
21.
Dysart J.“Diagnostic Companions.” Medical Marketing and Media. June 2014; 26–30; for Xalkori sales, see Datamonitor/Decision Resources Group database, 2016.
23.
Schnipper L,
Abel G. “Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health.”
JAMA Oncology. 2016; 2(11):1397–1398.
24.
Simon F,
Kotler P, op. cit, 114–116.
25.
Simon F,
Kotler P, op. cit, 149–151.
26.
Dobrow L.“Community Clash.” Medical Marketing and Media. April 2017; 31–39.
27.
Vranica S. “Catch Me If You Can.”
Wall Street Journal. June 22, 2016; R1;
Sharma A. “Big Media Needs to Embrace Digital Shift – Not Fight It.”
Wall Street Journal. June 22, 2016; R1, R2.
1.
Coulter A. “Patient Engagement—What Works?”
Journal of Ambulatory Care Management. 2012;35(2):80–89; see also
Coulter A,
Ellins J. “Effectiveness of Strategies for Informing, Educating and Involving Patients. ”
British Medical Journal. 2007;335(7609):24–27.
2.
Senior M.“Outcomes-Focused Payers, New Technologies and Empowered Consumers Are Pushing Pharma Towards Patient-Centric Drug Development and Commercialization.” Datamonitor Healthcare Trends Report, 2016.
4.
Parsons S,
Starling B,
Mullan-Jensen C,
Tham SG,
Warner K,
Wever K. “What the Public Knows and Wants to Know About Medicines Research and Development: A Survey of the General Public in Six European Countries.”
British Medical Journal Open. 2015;5: e006420. (doi: 10.1136/bmjopen-2014-006420); see also European Patients Academy website https://www.eupati.eu/.
6.
Insel R,
Dunne J,
Atkinson M,
Chiang J,
Dabelea D,
Gottlieb P, et al. “Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society and the American Diabetes Association.”
Diabetes Care. 2015;38: 1964–1974.
11.
Crew D.“Niche Treatments Become Big Business.” Financial Times. September 28, 2015:2.
12.
Wicks P,
Lowe M,
Gabriel S,
Sikirica S,
Sasane R,
Arcona S. “Increasing Patient Participation in Drug Development.”
Nature Biotechnology. 2015;33(2):135–136.
14.
Looney W.“Patient-Centered Strategies for Clinical Trials and Treatments.” Pharmaceutical Executive website. http://www.pharmexec.com/patient-centered-strategies-clinical-trials-treatment. Published September 9, 2016. Accessed May 1, 2017.; for ruxolitinib, see
Basch E. “Toward Patient-Centered Drug Development in Oncology.”
New England Journal of Medicine. 2013;369(5):397–400.
18.
Carman K,
Murer M,
Mangrum R,
Yang M,
Ginsburg M,
Sofaer S, et al. “Understanding an Informed Public's Views on the Role of Evidence in Making Healthcare Decisions.”
Health Affairs. 2016;35(4):566–574.
19. “Patients' and Consumers' Use of Evidence,
Datagraphic. ” Health Affairs. 2016;35(4):564–565;
Ranard B,
Werner R,
Antanavicius T,
Schwartz A,
Smith R,
Meisel Z, et al. “Yelp Reviews of Hospital Care Can Supplement and Inform Traditional Surveys of the Patient Experience of Care.”
Health Affairs. 2016;35(4):697–705.
21.
Findlay S. “Consumers' Interest in Provider Ratings Grows, and Improved Report Cards and Other Steps Could Accelerate Their Use.”
Health Affairs. 2016;35(4):688–695.
26.
Merlino J,
Raman A. “Health Care's Service Fanatics.”
Harvard Business Review. May 2013: 2–10.
27.
Sullivan HW,
Aikin KJ,
Squiers LB. “Quantitative Information on Oncology Prescription Drug Websites.”
Journal of Cancer Education. September 2, 2016: 1–4. Available at http://link.springer.com/article/10.1007/s13187-016-1107-1. Accessed May 1, 2017.
28.
Romito T.“Patient Services: Pharma's Best Kept Secret.” Accenture report, 2015; cited in Dobrow L, “Revolution.” Medical Marketing and Media, September 2015: 33–36.
29.
Khedkar P,
Sturgis M.“Want Better Access to Physicians? Understand What's Top of Mind: How to Broaden Your Reach—And Target Your Messaging—To Engage Healthcare Providers.” ZS Associates, 2016. Available at https://www.zs.com/-/media/pdfs/ph_mar_wp_afm_acm_2016_es_v4.pdf?la=en. Accessed May 1, 2017.
32.
Elton J,
O'Riordan A. Healthcare Disrupted: Next Generation Business Models and Strategies.
Hoboken, NJ:
John Wiley & Sons, 2016:97–99.
33.
Viswanathan M,
Golin CE,
Jones CD,
Ashok M,
Blalock S,
Wines R, et al. “Interventions to Improve Adherence to Self-Administered Medications for Chronic Disease in the United States.”
Annals of Internal Medicine. 2012;157:785–795.
34. Ibid.
35.
Robinson R. “Pharma's Role in Personalized Smart Health.”
PharmaVoice. May 2016:12–16.
36.
Wang R,
Blackburn G,
Desai M. “Accuracy of Wrist-Worn Heart Monitors.”
JAMA Cardiology. October 12, 2016. (doi: 10.1001/jamacardio.2016.3340).
37.
Beetsch J, Vice President Patient Advocacy, Celgene, personal communication with Françoise Simon, October 12, 2016.
38. “Celgene Corporation and Sage Bionetworks Announce Technology Collaboration to develop Observational Study Using the Apple ResearchKit Framework.” Celgene website. http://ir.celgene.com/releasedetail.cfm?releaseid=994085. Published October 18, 2016. Accessed May 1, 2017.
39. Bell D, Fox B, Olohan R. Pharma3D: Rewriting the Script for Marketing in the Digital Age. McKinsey e-book, April 2016. Available at www.pharma3D.com. Accessed May 1, 2017.
10.
Brooks M.“Big Pharma Pledges to Develop New Antibiotics, with Help.” Medscape website. http://www.medscape.com/viewarticle/857627. Published January 21, 2016. Accessed May 3, 2017.
13. Aitken M, Kleinrock M. “Understanding The Dynamics of Drug Expenditures.” QuintilesIMS Institute. Published July 11, 2017. Accessed July 12, 2017.
14.
Long D.“The Balance Between Innovation and Smarter Spending.” Presentation at the Health and Human Services Pharmaceutical Forum, Washington, DC, November 20, 2015.
17.
Vogler S,
Habl C,
Bogut M,
Voncina L. “Comparing Pharmaceutical Pricing and Reimbursement Policies in Croatia to the European Union Member States,”
Croatian Medical Journal. 2011;
52: 183–197.
18. WHO Collaboration Centre for Pharmaceutical Pricing and Reimbursement Policies. “Glossary.” http://whocc.goeg.at/Glossary/About. Accessed May 3, 2017.
31.
Neumann P,
Cohen J. “Measuring the Value of Prescription Drugs.”
New England Journal of Medicine. 2015;
373: 2595–2597.
32.
Simon F,
Kotler P. Building Global Biobrands: Taking Biotechnology to Market.
New York:
Free Press, 2003.
33.
Schleifer L.“The Pharma All-Stars.” Panel discussion at the 2015 Forbes Healthcare Summit, New York, New York, December 3, 2015.
34.
Garrison L,
Carlson J,
Bajaj P,
Towse, A,
Neumann P,
Sullivan S, et al. “Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects.”
American Journal of Managed Care. 2015;
21 (9): 632–640.
36.
Vioix, H,
Franzen S,
Selby D,
Collomb D,
Hauch O,
Emmas C. “Three Years of the Gefitinib UK Single Patient Access Scheme (SPA); Duration of Treatment for Patients with EGFR Mutation Positive NSCLC in NHS Clinical Practice.”
Value in Health. 2013;
16 (7): A425.
37.
Vioix H,
Franzen S,
Selby D, et al. “Duration of Gefitinib Treatment in EGFR Mutation Positive NSCLC Patients in a UK Single Payment Access Scheme.” Presented at ISPOR, June 3–7, 2012.
40.
McAllister E.“Results May Vary.” BioCentury. February 2, 2016.
41.
Sherman M, interview by E. Licking, January 4, 2016.
42. Garfield S, Sherman M, Longman R, Shiff S, and Licking E. “The Value Lab: Moving Value-Based Health Care from Theory to Practice.” In press. In Vivo Pharma Intelligence Website.
43.
Merrill J.“Multi-Indication Pricing: Big Hurdles and Actionable Options.” The Pink Sheet. May 30, 2016.
44.
Bach P. “Indication-Specific Pricing for Cancer Drugs.”
Journal of the American Medical Association. 2014;
312 (16): 1629–1630.
45. Revatio [package insert]. New York: Pfizer, Inc.; June 2005.
46. Viagra [package insert]. New York: Pfizer, Inc.; November 1988.
47. Center for Drug Evaluation and Research Application Number 125418Orig1s000 [memorandum]. Food and Drug Administration. July 27, 2012.
48.
Pearson S,
Dreitlein B,
Henshall C.“Indication-Specific Pricing of Pharmaceuticals in the United States Health Care System.” Institute for Clinical and Economic Review. March 2016.
49.
Miller S. Panel presentation at the Health and Human Services Pharmaceutical Forum, Washington DC, November 20, 2015.
50.
Bennette C,
Richards C,
Sullivan S,
Ramsey S. “Steady Increase in Prices for Oral Anticancer Drugs after Market Launch Suggests a Lack of Competitive Pressure.”
Health Affairs. 2016;
35: 805–812.
54.
Newcomer L. “Innovative Payment Models and Measurement for Cancer Therapy.”
Journal of Oncology Practice. 2014;
10: 187–189.
55.
Conway L.“What Can We Learn from United's Medical Oncology Episode-Based Payment Pilot?” Advisory Board Blog. Oncology Rounds. July 17, 2014.
56. Newcomer L. “Innovative Payment Models and Measurement for Cancer Therapy.” Journal of Oncology Practice. 2014; 10: 187–189.
57.
Appelby J.“United Healthcare Expands Effort to Rein in Rising Costs of Cancer Treatment.” Kaiser Health News. October 29. 2015.
58.
Mattke S,
Hoch E.“Borrowing for the Cure.” RAND Corporation, 2015.
59.
Montazerhodjat V,
Weinstock D,
Lo A. “Buying Cures versus Renting Health: Financing Health Care with Consumer Loans.”
Science Translational Medicine. 2016;
8: 1–8.
23. Institute for Clinical and Economic Review. “CardioMEMS HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks.” Revised Draft Review, October 9, 2015. Available at https://icer-review.org/wp-content/uploads/2016/01/CHF_Revised_Draft_Report_100915.pdf. Accessed May 5, 2017.
3.
Butler D. “When Google Got Flu Wrong.”
Nature. 2013;494(7436):155–156.
4. Institute of Medicine,“Transforming Clinical Research in the United States: Challenges and Opportunities,” Workshop Summary. National Academies Press, 2010; cited in Validic and Fierce Markets, “Advancing Drug Development with Digital Health: Four Key Ways to Integrate Patient-Generated Data into Trials.” March 2016.
5.
Lee SM.“How an IPhone Medical Research App Is Helping People with Asthma.” BuzzFeed News, September 29, 2015; cited in Validic, op. cit.
9.
Lott R. “New Players Join in the Drug Development Game.”
Health Affairs. 2014;33(10):1711–1713.
10.
Al-Faruque F. “Novartis and Qualcomm Partner in mHealth.” In Vivo Pharma Intelligence website. https://www.pharmamedtechbi.com/publications/in-vivo/33/1/novartis-and-qualcomm-partner-in-mhealth?p=1. Published January 27, 2015. Accessed May 8, 2017; Zimmerman Carolyne, Executive Director, Global Business Development and Licensing and Novartis Lead for dRx Capital, personal communication with Françoise Simon, October 20, 2015.
12.
Lipset C. “Engage with Research Participants about Social Media.”
Nature Medicine. 2014;20(3):231; Lipset Craig, Head of Clinical Innovation for Worldwide Research & Development, Pfizer; personal communication with Françoise Simon, October 15, 2015.
13.
Roman DH,
Conlee KD. The Digital Revolution Comes to US Healthcare. Goldman Sachs report, June 29, 2015.
14.
Matthews C,
Jones A. “Pfizer Blocks the Use of Drugs in Executions.”
Wall Street Journal. May 14/15, 2016: A3.
26. Accenture 2015 survey; cited in Dobrow L. “Revolution.” Medical Marketing & Media. September 2015: 33–36.
27. World Health Organization.“mHealth: New Horizons for Health through Mobile Technologies.” Global Observatory for eHealth Series, Vol. 3, 2011; cited in IMS Institute for Healthcare Informatics, Patient Adoption of mHealth, September 2015.
28. “Things Are Looking App.” The Economist. March 12, 2016: 59–60.
29.
Gallagher D. “Google Clicks in a Peak Smartphone Age.”
Wall Street Journal. May 16, 2016: C6.
30. IMS Institute for Healthcare Informatics, Patient Adoption of mHealth, September 2015.
32.
McCaffrey K.“Biogen, PatientsLikeMe Use Fitbit to Better Understand Multiple Sclerosis.” Medical Marketing & Media website. http://www.mmm-online.com/digital/biogen-patientslikeme-use-fitbit-to-better-understand-ms/article/409279/. Published April 15, 2015. Accessed May 8, 2017; see also Block VJ, Lizee A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Traublay M, Gourraud PA, et al., “Continuous daily assessment of multiple sclerosis disability using remote step count monitoring,” J. Neurology (2017) 264:316–326 (doi 10. 1007/s00415-016-8334-6), published online November 28, 2016.
33.
Epper Hoffman K. “First Sign of Defense.”
Medical Marketing & Media. April 2016: 40–41.
34.
Serrano K,
Yu M,
Riley W,
Patel V,
Hughes P,
Marchesini K, et al. “Willingness to Exchange Health Information Via Mobile Devices: Findings from a Population-Based Survey.”
Annals of Family Medicine. 2016;14(1):36–40.
35.
Blenner S,
Kollmer M,
Rouse A,
Daneshvar N,
Williams C,
Andrews L. “Privacy Policies of Android Diabetes Apps and Sharing of Health Information.”
Journal of the American Medical Association. 2016;315(10):1051–1052.
36. FDA Draft Guidance, Use of Electronic Informed Consent in Clinical Investigations, March 2015, Center for Drug Evaluation and Research. Silver Spring, MD.
37.
Cortez M,
Cohen G,
Kesselheim A. “FDA Regulation of Mobile Health Technologies.”
New England Journal of Medicine. 2014;371(4):372–379.
38.
Yang T.
Silverman R. “Mobile Health Applications: The Pattern of Legal and Liability Issues Suggests Strategies to Improve Oversight.”
Health Affairs. 2014;33(2); 222–227.
40. Decision Resources Group. Cybercitizen Health® U.S. 2015.
41.
Findlay S. “Consumers' Interest in Provider Ratings Grows, and Improved Report Cards and Other Steps Could Accelerate Their Use.”
Health Affairs. 2016;35(4):688–705.
42.
Kear T,
Harrington M,
Bhattacharya A. “Partnering with Patients Using Social Media to Develop a Hypertension Management Instrument.”
Journal of the American Society of Hypertension. 2015;9(9):725–734.
45.
Rhyee C,
Auh J,
Wachter Z. Telehealth: Bringing Health Care to Your Fingertips. Ahead of the Curve Series. Cowen Equity Research. February 20, 2015.
46.
Schwamm L. “Telehealth: Seven Strategies to Successfully Implement Disruptive Technology and Transform Healthcare.”
Health Affairs. 2014;33(2):200–206; See also
Kvedar J,
Coye MJ,
Everett W. “Connected Health: A Review of Technologies and Strategies to Improve Patient Care with Telemedicine and Telehealth.”
Health Affairs. 2014;33(2):194–199.
47. Decision Resources Group.Taking the Pulse U.S. 2015 Physician Research Module. Physician Mobile Strategy in 2016: Optimizing Fundamentals and Driving Innovation; see also Rhyee C, Wachter Z, Auh J. Online Content Providers: From Portal to Platform. Ahead of Curve Series. Cowen Equity Research, September 16, 2015.
48.
Rhyee C, et al., Online Health Content Providers, op. cit.
49.
Beck M. “Websites Misdiagnose Ailments.”
Wall Street Journal. May 16, 2016: A6.
50.
Rhyee, C et al, Telehealth: Bringing Healthcare to Your Fingertips. op. cit.
52.
Cryer L,
Shannon S,
Van Amsterdam M,
Leff B. “Costs for ‘Hospital at Home’ Patients Were 19 Percent Lower, with Equal or Better Outcomes Compared to Similar Inpatients.”
Health Affairs. 2012;31(6):1237–1243.
53.
Rhyee C. Telehealth: Bringing Healthcare to Your Fingertips, op. cit.
Chapter 10
1.
Siegel E. Predictive Analytics: The Power to Predict Who Will Click, Buy, Lie, or Die.
Hoboken, NJ:
John Wiley & Sons, 2016.
2. Gartner Group. “Gartner Says 6.4 Billion Connected ‘Things’ Will Be in Use in 2016, Up 30% From 2015.” http://www.gartner.com/newsroom/id/3165317. Published November 10, 2015. Accessed May 9, 2017.
6.
Lavorgna M. “There's No Such Thing as Digital: A Conversation with Charles Hansen, Gordon Rankin, and Steve Silberman.” Audiostream website. http://www.audiostream.com/content/draft#XArQrlELGYJSdpw6.99. Published June 24, 2013. Accessed May 9, 2017.
16.
Perjasamy M,.
Raj P. “Big Data Analytics: Enabling Technologies and Tools.” In Mahmood Z, Data Science and Big Data Computing.
New York:
Springer International Publishing, 2016: 221–243.
17.
Hill C. Personal interview by E. Licking. August 9, 2016.
25. National Human Genome Research Institute, “The Cost of Sequencing a Human Genome.” https://www.genome.gov/27565109/the-cost-of-sequencing-a-human-genome/. Published July 6, 2016. Accessed May 9, 2017; see also Herper M. “Illumina Promises to Sequence Human Genome for $100--But Not Quite Yet.” Forbes, January 9, 2017. Accessed July 6, 2017.
33.
Hay M,
Thomas D,
Craighead J,
Economides C,
Rosenthal J. “Clinical Development Success Rates for Investigational Drugs.”
Nature Biotechnology. 2014;32:40–51.
34.
Akmaev S. Personal interview by E. Licking. July 28, 2016.
35.
Bhatt A. “Evolution of Clinical Research: A History Before and Beyond James Lind.” Perspectives in Clinical Research. 2010;1(1): 6–10.
45.
Eichler HG. et al. “From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-Span Approach to Bring New Drugs to Patients.”
Clinical Pharmacology and Therapeutics. 2015; (97):234–246.
61.
Lund S,
Manyika J,
Nyquist S,
Mendonca L,
Ramaswamy M. Game Changers: Five Opportunities for US Growth and Renewal. McKinsey Global Institute, July 2013.
62.
Senior M. Data in Healthcare: Underpinning the Shift to Value. Datamonitor Healthcare. November 22, 2016.
63.
Kiron D,
Kirk Prentice P,
Ferguson RB. “The Analytics Mandate.” Findings from the 2014 Data and Analytics Global Executive Study and Research Report.
MIT Sloan Management Review. 2014; Winter: 3–21.